Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137027 | 0.87 | — | — | |
| SCHEMBL18544357 | 0.85 | GABBR2 (0.31) | — | |
| SCHEMBL29042231 | 0.84 | TSHR (0.40) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL2268617 | 0.82 | MEN1 (0.47) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL27650343 | 0.82 | MEN1 (0.46) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL1004323 | 0.82 | MEN1 (0.47) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL261546 | 0.82 | MEN1 (0.47) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL19733097 | 0.80 | MEN1 (0.44) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL20935410 | 0.80 | TSHR (0.35) | MEN1KMT2ATSHRMAPK1ALDH1A1 | |
| SCHEMBL19000738 | 0.79 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170051105-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170051105-A1 | VITAMIN FUNCTIONALIZED GEL-FORMING BLOCK COPOLYMERS FOR BIOMEDICAL APPLICATIONS | VDR, PROC, CYP24A1 | MEN1 1213/4885KMT2A 3993/4885TSHR 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.